^
Association details:
| Biomarker: | PTGS2 positive + MET positive + PBK positive + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells
Published date:
10/14/2019
Excerpt:
Here, COX2, TOPK, and MET expression were examined in EGFR-activating mutated NSCLC...of 153 patients with EGFR-activating mutations, we identified that the PFS of gefitinib-resistant patients who were COX2, MET, and TOPK triple-positive was shorter than that of patients who were triple-negative…These results indicated that triple-positive patients with COX2, MET, and TOPK had a worse prognosis.
DOI:
10.1038/s41419-019-2020-4
